Welcome

Sign out Have a question? We're here to help

Sign out

Adaptimmune Ther Ads (ADAP)

$2.83 0.17 (5.67%)

16:00 EDT ADAP Stock Quote Delayed 20 Minutes

Volume:

Previous Close $3.00

Market Cap 266.43M

PE Ratio -3.93

EPS -0.72

Volume (Avg. Vol.) 145,229

Day's Range 2.81 - 3.05

52-Week Range 0.71 - 6.00

Dividend & Yield N/A (N/A)

ADAP Stock Predictions, Articles, and Adaptimmune Ther Ads News

From the Web

Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March

From The Motley Fool Apr 6, 2020

These three clinical-stage biotechs are all bargains after last month's marketwide downturn.

Top Pharma Stocks Under $5

From The Motley Fool Mar 24, 2020

These clinical-stage drugmakers could be a steal at current levels.

First Week of ADAP April 17th Options Trading

From Market News Video Mar 10, 2020

Investors in Adaptimmune Therapeutics PLC (ADAP) saw new options become available this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADAP options chain for the new April 17th contracts and identified the following put contract of particular interest.

Stock Charts To Watch - Thursday, March 5

From Talk Markets Mar 6, 2020

BioXcel Therapeutics, Inc. has a really nice-looking pattern.

Earnings Update: Adaptimmune Therapeutics plc Just Reported And Analysts Are Boosting Their Estimates

From Simply Wall St Feb 29, 2020

Adaptimmune Therapeutics plc (NASDAQ:ADAP) missed earnings with its latest yearly results, disappointing overly-optimistic analysts. It looks to have been a weak result overall, as sales of US$1.1m were 42% less<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adap/adaptimmune-therapeutics/news/earnings-update-adaptimmune-therapeutics-plc-just-reported-and-analysts-are-boosting-their-estimates/">Read More...</a></div>

Adaptimmune Therapeutics (ADAP) Receives a Hold from JonesTrading

From Analyst Ratings Feb 27, 2020

In a report released today, Soumit Roy from JonesTrading reiterated a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report). The company’s shares closed last Monday at $3.57. According to TipRanks.com, Roy is a 4-star analyst with an average return of 16.2% and a 37.8% success rate. Roy covers the Healthcare sector, focusing on stocks

Navellier Ratings

Total Grade

Buy

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Welcome

Breaking news

Adaptimmune Ther Ads (ADAP)

Navellier Ratings

Total Grade

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Already a subscriber?

Welcome

Breaking news

Adaptimmune Ther Ads (ADAP)

ADAP Stock Predictions, Articles, and Adaptimmune Ther Ads News

Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March

Top Pharma Stocks Under $5

First Week of ADAP April 17th Options Trading

Stock Charts To Watch - Thursday, March 5

Earnings Update: Adaptimmune Therapeutics plc Just Reported And Analysts Are Boosting Their Estimates

Adaptimmune Therapeutics (ADAP) Receives a Hold from JonesTrading

Navellier Ratings

Total Grade

Subscriber Sign in